

76-04-0

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

EIGE, et al.

Serial No.:

09/840,277

Group Art Unit No.:

Filed:

April 23, 2001

Examiner:

For:

INTEGRIN/ADHESION ANTAGONISTS

Docket No.:

A-688A

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

As a means of complying with the duty of disclosure, applicants submit a "List of References Cited by Applicant" on a modified PTO-1449 formand provides a copy of each of the listed references for consideration by the Examiner.

Each item contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than 30 days prior to the filing of this statement, pursuant to 37 C.F.R. 1.704(d). The Applicants provision of these references under this and any other Information Disclosure Statement should not be deemed an admission that all such references are relevant to patentability nor are necessarily prior art in accordance with 35 U.S.C. §102.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

Respectfully submitted,

Timothy & Gay

Attorney for Applicants

Registration No.: 33,111 Phone: (805) 447-2688

Date: May 30, 2002

Please send all future correspondence to:

US Patent Operations/TJG Dept. 4300, M/S 27-4-A AMGEN INC. One Amgen Center Drive

Thousand Oaks, California 91320-1799

EXPRESS MAIL CERTIFICATE

"Express Mail" mail labeling number: EL360693996US

May 30,

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addre indicated above and is addressed to Box Patent Application, Assistant Commissioner for Patents, Washi

m